Filing Flows › Whitehawk Therapeutics (WHWK) › Q4 2024
Whitehawk Therapeutics (WHWK) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 28, 2025
Whitehawk Therapeutics (WHWK) reported revenue of $7.2M for the fourth quarter 2024 (Q4 2024), +14% from a year earlier and +0.4% from the quarter before. Operating margin was -261.8%, net loss $18.3M (252.4% of revenue).
Whitehawk Therapeutics, Q4 2024: revenue $7.2M (+14% year over year), operating margin -261.8%, net loss $18.3M, operating cash flow −$15.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.2M | +0.4% | +14% |
| Operating profit | −$18.9M | — | — |
| Net earnings | −$18.3M | — | — |
| Operating cash flow | −$15.1M | — | — |
What changed
Revenue was $7.2M in Q4 2024, up 14% year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $18.9M, an operating margin of -261.8%. Total costs grew 9% against revenue growth of 14%. The fastest-growing cost line was Research & development (+12%). The quarter ended with a net loss of $18.3M, wider than the previous quarter's $12.5M loss.
Operating cash flow was −$15.1M. Non-cash charges added back $54K of depreciation and $1.9M of share-based compensation. Working capital and other items added $1.3M. Capital expenditures of $186K exceeded it, leaving free cash flow of −$15.2M.
Questions
What was Whitehawk Therapeutics' revenue in the fourth quarter 2024?
Whitehawk Therapeutics (WHWK) reported revenue of $7.2M for the fourth quarter 2024 (Q4 2024), +14% from a year earlier and +0.4% from the quarter before.
Was Whitehawk Therapeutics profitable in the fourth quarter 2024?
Operating loss was $18.9M (-261.8% of revenue) and net loss $18.3M.